FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2139604531> ?p ?o ?g. }

• W2139604531 endingPage "52" @default.
• W2139604531 startingPage "44" @default.
• W2139604531 abstract "BackgroundInhaled corticosteroids (ICSs) have been shown to reverse epithelial damage and decrease lamina reticularis thickness in patients with asthma.ObjectiveThis study investigated whether clinical asthma control and airway inflammation could be maintained after switching therapy from medium-dose fluticasone propionate (FP) to low-dose FP administered with the long-acting β2-agonist (LABA) salmeterol.MethodsEighty-eight subjects (age, ≥18 years) who, during open-label screening, demonstrated improved asthma control after an increase from 100 μg of FP twice daily to 250 μg of FP twice daily were randomized to receive 100/50 μg of FP/salmeterol through a Diskus inhaler (GlaxoSmithKline, Research Triangle Park, NC) twice daily or continue 250 μg of FP twice daily through a Diskus inhaler for 24 weeks. Clinical outcomes were monitored, and bronchial biopsy specimens and bronchoalveolar lavage fluid were obtained before and after 24 weeks of treatment.ResultsThere were no significant differences between treatments with respect to eosinophils in the bronchial mucosa and bronchoalveolar lavage fluid; mucosal mast cells, neutrophils, or CD3+, CD4+, CD8+, or CD25+ T lymphocytes; or concentration of mediators (GM-CSF, IL-8, and eosinophil cationic protein). The 2 treatments were not different with respect to lamina reticularis thickness. Consistent with the airway inflammatory measures, clinical and physiologic measures of asthma control were also similar.ConclusionThis study demonstrates that control of asthma and airway inflammation is maintained over the 24-week treatment period when patients requiring a medium-dose ICS are switched to a lower-dose ICS with a LABA.Clinical implicationsA lower-dose ICS with a LABA is effective in controlling inflammation and providing clinical asthma control, confirming current guideline recommendations. Inhaled corticosteroids (ICSs) have been shown to reverse epithelial damage and decrease lamina reticularis thickness in patients with asthma. This study investigated whether clinical asthma control and airway inflammation could be maintained after switching therapy from medium-dose fluticasone propionate (FP) to low-dose FP administered with the long-acting β2-agonist (LABA) salmeterol. Eighty-eight subjects (age, ≥18 years) who, during open-label screening, demonstrated improved asthma control after an increase from 100 μg of FP twice daily to 250 μg of FP twice daily were randomized to receive 100/50 μg of FP/salmeterol through a Diskus inhaler (GlaxoSmithKline, Research Triangle Park, NC) twice daily or continue 250 μg of FP twice daily through a Diskus inhaler for 24 weeks. Clinical outcomes were monitored, and bronchial biopsy specimens and bronchoalveolar lavage fluid were obtained before and after 24 weeks of treatment. There were no significant differences between treatments with respect to eosinophils in the bronchial mucosa and bronchoalveolar lavage fluid; mucosal mast cells, neutrophils, or CD3+, CD4+, CD8+, or CD25+ T lymphocytes; or concentration of mediators (GM-CSF, IL-8, and eosinophil cationic protein). The 2 treatments were not different with respect to lamina reticularis thickness. Consistent with the airway inflammatory measures, clinical and physiologic measures of asthma control were also similar. This study demonstrates that control of asthma and airway inflammation is maintained over the 24-week treatment period when patients requiring a medium-dose ICS are switched to a lower-dose ICS with a LABA." @default.
• W2139604531 created "2016-06-24" @default.
• W2139604531 creator A5004903602 @default.
• W2139604531 creator A5005205857 @default.
• W2139604531 creator A5009563289 @default.
• W2139604531 creator A5014443305 @default.
• W2139604531 creator A5025219391 @default.
• W2139604531 creator A5027127170 @default.
• W2139604531 creator A5029859348 @default.
• W2139604531 creator A5033448861 @default.
• W2139604531 creator A5037089007 @default.
• W2139604531 creator A5037168372 @default.
• W2139604531 creator A5043576559 @default.
• W2139604531 creator A5047450563 @default.
• W2139604531 creator A5053470188 @default.
• W2139604531 creator A5062711392 @default.
• W2139604531 creator A5072015628 @default.
• W2139604531 creator A5076439834 @default.
• W2139604531 creator A5083411289 @default.
• W2139604531 creator A5084946954 @default.
• W2139604531 date "2006-07-01" @default.
• W2139604531 modified "2023-09-27" @default.
• W2139604531 title "Control of airway inflammation maintained at a lower steroid dose with 100/50 μg of fluticasone propionate/salmeterol" @default.
• W2139604531 cites W1945512486 @default.
• W2139604531 cites W1970648068 @default.
• W2139604531 cites W1971467868 @default.
• W2139604531 cites W1976829610 @default.
• W2139604531 cites W1995257163 @default.
• W2139604531 cites W1995797675 @default.
• W2139604531 cites W2003199954 @default.
• W2139604531 cites W2013037468 @default.
• W2139604531 cites W2016025974 @default.
• W2139604531 cites W2028637591 @default.
• W2139604531 cites W2051948045 @default.
• W2139604531 cites W2068789291 @default.
• W2139604531 cites W2072173344 @default.
• W2139604531 cites W2078646546 @default.
• W2139604531 cites W2085140273 @default.
• W2139604531 cites W2103114025 @default.
• W2139604531 cites W2106399406 @default.
• W2139604531 cites W2107458343 @default.
• W2139604531 cites W2108073684 @default.
• W2139604531 cites W2109795756 @default.
• W2139604531 cites W2130823712 @default.
• W2139604531 cites W2139297598 @default.
• W2139604531 cites W2154263136 @default.
• W2139604531 cites W2155345300 @default.
• W2139604531 cites W2159453469 @default.
• W2139604531 cites W2169949930 @default.
• W2139604531 cites W2308777632 @default.
• W2139604531 cites W2341674111 @default.
• W2139604531 cites W4236639597 @default.
• W2139604531 doi "https://doi.org/10.1016/j.jaci.2006.03.043" @default.
• W2139604531 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16815137" @default.
• W2139604531 hasPublicationYear "2006" @default.
• W2139604531 type Work @default.
• W2139604531 sameAs 2139604531 @default.
• W2139604531 citedByCount "38" @default.
• W2139604531 countsByYear W21396045312012 @default.
• W2139604531 countsByYear W21396045312013 @default.
• W2139604531 countsByYear W21396045312014 @default.
• W2139604531 countsByYear W21396045312016 @default.
• W2139604531 countsByYear W21396045312018 @default.
• W2139604531 countsByYear W21396045312019 @default.
• W2139604531 countsByYear W21396045312020 @default.
• W2139604531 crossrefType "journal-article" @default.
• W2139604531 hasAuthorship W2139604531A5004903602 @default.
• W2139604531 hasAuthorship W2139604531A5005205857 @default.
• W2139604531 hasAuthorship W2139604531A5009563289 @default.
• W2139604531 hasAuthorship W2139604531A5014443305 @default.
• W2139604531 hasAuthorship W2139604531A5025219391 @default.
• W2139604531 hasAuthorship W2139604531A5027127170 @default.
• W2139604531 hasAuthorship W2139604531A5029859348 @default.
• W2139604531 hasAuthorship W2139604531A5033448861 @default.
• W2139604531 hasAuthorship W2139604531A5037089007 @default.
• W2139604531 hasAuthorship W2139604531A5037168372 @default.
• W2139604531 hasAuthorship W2139604531A5043576559 @default.
• W2139604531 hasAuthorship W2139604531A5047450563 @default.
• W2139604531 hasAuthorship W2139604531A5053470188 @default.
• W2139604531 hasAuthorship W2139604531A5062711392 @default.
• W2139604531 hasAuthorship W2139604531A5072015628 @default.
• W2139604531 hasAuthorship W2139604531A5076439834 @default.
• W2139604531 hasAuthorship W2139604531A5083411289 @default.
• W2139604531 hasAuthorship W2139604531A5084946954 @default.
• W2139604531 hasConcept C105922876 @default.
• W2139604531 hasConcept C126322002 @default.
• W2139604531 hasConcept C2776042228 @default.
• W2139604531 hasConcept C2776719499 @default.
• W2139604531 hasConcept C2777037409 @default.
• W2139604531 hasConcept C2777714996 @default.
• W2139604531 hasConcept C2777961210 @default.
• W2139604531 hasConcept C2779028295 @default.
• W2139604531 hasConcept C2781212218 @default.
• W2139604531 hasConcept C42219234 @default.
• W2139604531 hasConcept C71924100 @default.
• W2139604531 hasConcept C88675164 @default.
• W2139604531 hasConcept C90924648 @default.
• W2139604531 hasConceptScore W2139604531C105922876 @default.

• next